Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Pfizer Inc. | Verdiperstat | Multiple system atrophy (MSA) | Phase 3 | Trial Discontinued | Oral | Neurology |
| Pfizer Inc. | TRORILUZOLE | Generalized anxiety disorder (GAD) | Phase 3 | Trial Discontinued | Oral | Psychiatric |
| Pfizer Inc. | BAVENCIO (avelumab) - JAVELIN Ovarian 100 | Ovarian cancer | Phase 3 | Intravenous | Oncology | |
| Pfizer Inc. | PF-06939926 (CIFFREO) | Duchenne muscular dystrophy (DMD) | Phase 3 | Data Released | intravenous | Genetic Disorder |
| Pfizer Inc. | INLYTA (axitinib) | Recurrent renal cell carcinoma (RCC) | Phase 3 | oral | Oncology | |
| Pfizer Inc. | Vadastuximab Talirine - (CASCADE) | Acute myeloid leukemia (AML) - cancer | Phase 3 | Trial Discontinued | Intravenous | Oncology |
| Pfizer Inc. | ARRY 797 | LMNA A/C-related dilated cardiomyopathy (DCM) | Phase 3 | Oral | Genetic Disorder | |
| Pfizer Inc. | XTANDI (Enzalutamide) - (ENDEAR) | Triple negative breast cancer | Phase 3 | Oral | Oncology |
